Hwail Pharm

At a glance

Hwail Pharm filed 44 disclosures in the last 12 months, including 9 insider, 8 5% holder, 2 issuance and 1 buyback. The most recent key filing was on Sep 18.

Revenue for 2025 was ₩101B, down 15.8% on 2024. It made an operating loss of ₩2.3B. Debt was 3% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩47.9B and operating loss of ₩1.5B.

The 2025 annual report lists 145 employees with an average tenure of 8.5 years and average pay of ₩61.7M, #886 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩114M each on average. It paid no cash dividend for 2025. 오성첨단소재(주) and related parties held 36.87% at year end.

From the 2025 annual report

Staff: 145 (97 men, 48 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩8.9B. Directors and auditors: 6, paid ₩685M in total.

No cash dividend was paid for 2025.

Largest shareholder

오성첨단소재(주) holds 25.49%; with 3 related parties the group holds 36.87% of common shares at year end (from 34.73% at the start of the year).

Auditor: 신우회계법인 · opinion: Unqualified.

Rankings: Low debt #2 of 1,372

Source: 2025 annual business report (DART). How figures are combined

Financial summary